Back to search
FDAFDA · Food and drugs·Recall number D-0493-2017

Mirtazapine Tablets, USP, 45 mg. Rx only, 100 Tablets (10 X 10). Manufactured by: Mylan Pharmaceuticals Inc, Morgantown, WV ---NDC 51079-088-20

Published March 15, 2017 · Recall initiated: January 27, 2017

Summary

FDA records drug Class II recall D-0493-2017, published March 15, 2017 and initiated January 27, 2017. Recalling firm: Mylan Institutional, Inc. (d.b.a. UDL Laboratories); Status: Terminated; Reported quantity: 58 UD100 Unit Dose Blister Cards of 10 (10 cards of 10 tablets each); Lot: Batch #3083289; Exp. Date 12/2018. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of Foreign Tablets/Capsules; possibility of Glipizide 10 mg tablets commingled

What to do

Voluntary: Firm initiated · Letter

Get an email if MIRTAZAPINE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
MIRTAZAPINE
Manufacturer
Mylan Institutional, Inc. (d.b.a. UDL Laboratories)
Distributor
Nationwide
Lot
Batch #3083289; Exp. Date 12/2018
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Mirtazapine Tablets, USP, 45 mg. Rx only, 100 Tablets (10 X 10). Manufactured by: Mylan Pharmaceuticals Inc, Morgantown, WV ---NDC 51079-088-20 recalled?

Yes. FDA published recall D-0493-2017 on March 15, 2017. Reported hazard: Presence of Foreign Tablets/Capsules; possibility of Glipizide 10 mg tablets commingled

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: MIRTAZAPINE.